Dr Landgren on Recent Treatment Paradigm Changes in Multiple Myeloma

“The speed of change [in the multiple myeloma field] is just increasing, and I think components of that change are driven by the new therapies. We have a lot of immunotherapies in the field of myeloma, and I do think that myeloma is probably one of the pioneering diseases for chemotherapy-free treatment concepts.”

C. Ola Landgren, MD, PhD, professor of medicine, chief, Division of Myeloma, Department of Medicine, University of Miami, Miller School of Medicine; director, Sylvester Myeloma Institute; co-leader, Translational and Clinical Oncology Program, Paul J. DiMare Endowed Chair in immunotherapy, Sylvester Comprehensive Cancer Center, discusses the treatment trajectory in the multiple myeloma field. He highlighted changes during the 2024 ASH Annual Meeting.

Within the past 10 to 15 years, the field of multiple myeloma has undergone many changes regarding treatment approaches, Landgren says. However, he explains there are still more changes to come in the next several years. A significant contributor to these growing changes includes immunotherapies in the space, he continues. In current times, he says that multiple myeloma is a disease that has many chemotherapy-free treatment options. The treatment armamentarium now includes monoclonal antibodies and bispecific antibodies, along with others in development.

From an efficacy standpoint, the emergence of novel classes of drugs has helped the treatment paradigm moves further away from chemotherapy options in multiple myeloma while still improving outcomes. Landgren concludes that there are many continual advantages with chemotherapy-free treatment options, and he looks forward to seeing more developments in the multiple myeloma spaces with new cellular therapies, combination regimens, and treatment strategies.